Targeting mitochondrial unfolded protein response to develop novel cancer therapeutics 

The mitochondrial unfolded protein response (UPRmt) is crucial for maintenance of mitochondrial protein homeostasis (proteostasis), cellular functions, and survival. 

We identified that the two key components of the UPRmt, heat shock protein 60 (HSP60, a mitochondrial chaperonin) and caseinolytic protease (ClpP, a mitochondrial protease), are required for the development of advanced prostate cancer. 

Figure from a scientific research study

HSP60 maintains bioenergetic function (ATP producing function) of mitochondria via interacting with ClpP. We identified a novel UPRmt inhibitor that blocks HSP60 interaction with ClpP and abrogates survival signaling. 

Our goal is to develop UPRmt-based novel therapeutics for prostate and other types of aggressive cancer. 

Related publications

Connect with the Chandra Lab 

Phone: 716-845-4882 

Department of Pharmacology & Therapeutics 
Roswell Park Comprehensive Cancer Center 
Elm and Carlton Streets 
Buffalo, NY 14263